{
  "symbol": "EVOK",
  "company_name": "Evoke Pharma",
  "ir_website": "https://evokepharmainc.gcs-web.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://evokepharmainc.gcs-web.com/press-releases",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Evoke Pharma](/sites/g/files/knoqqb59611/themes/site/nir_pid1515/client/images/EVOKE-PC.png) ![Evoke Pharma](/sites/g/files/knoqqb59611/themes/site/nir_pid1515/client/images/EVOKE-PC.png) ](https://devevokepharma.wpengine.com/)\n\n[](#)\n\n[evokepharma](https://www.evokepharma.com/author/evokepharma/ \"Posts by evokepharma\")\n\n#  Press Releases \n\nYear: - Any -202420232022202120202019201820172016201520142013\n\n- Any -\n\n[Date](?items_per_page=10&order=field_nir_news_date&sort=asc \"sort by Date\") | [Title and Summary](?items_per_page=10&order=field_nir_news_title&sort=asc \"sort by Title and Summary\") | Additional Formats  \n---|---|---  \n[Toggle Summary](#) Nov 07, 2024 |  [Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results](/news-releases/news-release-details/evoke-pharma-inc-reports-third-quarter-2024-financial-results) GIMOTI third quarter net product sales of $2.7 million , highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52% year-over-year prescription fill increase; 39% increase since Q1 2024 Real-world data presented at ACG 2024  |  [View HTML](/news-releases/news-release-details/evoke-pharma-inc-reports-third-quarter-2024-financial-results) [PDF Version](/node/11031/pdf)  \n[Toggle Summary](#) Oct 28, 2024 |  [Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®](/news-releases/news-release-details/evoke-pharma-eversana-announce-statistically-significant) Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All Cause Emergency Department Visits (-91%, p=0.001), All Cause Office Visits (-41%, p=0.027) and All  |  [View HTML](/news-releases/news-release-details/evoke-pharma-eversana-announce-statistically-significant) [PDF Version](/node/11006/pdf)  \n[Toggle Summary](#) Oct 23, 2024 |  [Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting](/news-releases/news-release-details/evoke-pharma-showcase-award-winning-research-2024-american) SOLANA BEACH, Calif. , Oct. 23, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. &nbsp;(NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ® &nbsp;(metoclopramide) nasal spray, announced upcoming poster presentations at  |  [View HTML](/news-releases/news-release-details/evoke-pharma-showcase-award-winning-research-2024-american) [PDF Version](/node/11001/pdf)  \n[Toggle Summary](#) Oct 22, 2024 |  [Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors](/news-releases/news-release-details/evoke-pharma-announces-appointment-ben-smeal-board-directors) SOLANA BEACH, Calif. , Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc.&nbsp; (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti ® &nbsp;(metoclopramide) nasal spray, announced the appointment of Ben Smeal to  |  [View HTML](/news-releases/news-release-details/evoke-pharma-announces-appointment-ben-smeal-board-directors) [PDF Version](/node/10981/pdf)  \n[Toggle Summary](#) Oct 01, 2024 |  [Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion](/news-releases/news-release-details/evoke-pharma-announces-proceeds-existing-warrants-and-board) Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16 /share SOLANA BEACH, Calif. , Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI)  |  [View HTML](/news-releases/news-release-details/evoke-pharma-announces-proceeds-existing-warrants-and-board) [PDF Version](/node/10956/pdf)  \n[Toggle Summary](#) Sep 19, 2024 |  [Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments](/news-releases/news-release-details/evoke-pharma-reaffirms-its-commitment-patients-gastroparesis) Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis SOLANA BEACH, Calif. , Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. &nbsp;(NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with  |  [View HTML](/news-releases/news-release-details/evoke-pharma-reaffirms-its-commitment-patients-gastroparesis) [PDF Version](/node/10926/pdf)  \n[Toggle Summary](#) Sep 09, 2024 |  [Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference](/news-releases/news-release-details/evoke-pharma-participate-gastroenterology-and-hepatology) SOLANA BEACH, Calif. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc.&nbsp;(NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® &nbsp;(metoclopramide) nasal spray, announced that management will participate  |  [View HTML](/news-releases/news-release-details/evoke-pharma-participate-gastroenterology-and-hepatology) [PDF Version](/node/10921/pdf)  \n[Toggle Summary](#) Sep 04, 2024 |  [Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference](/news-releases/news-release-details/evoke-pharma-present-hc-wainwrights-26th-annual-global) SOLANA BEACH, Calif. , Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc.&nbsp;(NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® &nbsp;(metoclopramide) nasal spray,&nbsp;announced that management will participate  |  [View HTML](/news-releases/news-release-details/evoke-pharma-present-hc-wainwrights-26th-annual-global) [PDF Version](/node/10911/pdf)  \n[Toggle Summary](#) Aug 13, 2024 |  [Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results](/news-releases/news-release-details/evoke-pharma-inc-reports-second-quarter-2024-financial-results) GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million Achieved record-high prescription fills during Q2 75% year-over-year prescription fill increase; 32% growth compared to Q1 2024 Two abstracts  |  [View HTML](/news-releases/news-release-details/evoke-pharma-inc-reports-second-quarter-2024-financial-results) [PDF Version](/node/10866/pdf)  \n[Toggle Summary](#) Aug 08, 2024 |  [Evoke Pharma, Inc. Supports Gastroparesis Awareness Month](/news-releases/news-release-details/evoke-pharma-inc-supports-gastroparesis-awareness-month) Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif. , Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused  |  [View HTML](/news-releases/news-release-details/evoke-pharma-inc-supports-gastroparesis-awareness-month) [PDF Version](/node/10846/pdf)  \n  \nDisplaying 1 - 10 of 233 results\n\n[Go to Top](#)\n\n[Go to Top](#)\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://evokepharmainc.gcs-web.com/sec-filings",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Evoke Pharma](/sites/g/files/knoqqb59611/themes/site/nir_pid1515/client/images/EVOKE-PC.png) ![Evoke Pharma](/sites/g/files/knoqqb59611/themes/site/nir_pid1515/client/images/EVOKE-PC.png) ](https://devevokepharma.wpengine.com/)\n\n[](#)\n\n[evokepharma](https://www.evokepharma.com/author/evokepharma/ \"Posts by evokepharma\")\n\n#  SEC Filings \n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year - Any -202420232022202120202019201820172016201520142013201220112010200920082007\n\n- Any -\n\n[Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | View  \n---|---|---|---  \nNov 22, 2024 | [424B5](/sec-filings/sec-filing/424b5/0000950170-24-130258) | Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3 |  [0000950170-24-130258.pdf](/static-files/f4028127-b30d-45eb-af9c-f039a9d3c161) [0000950170-24-130258.rtf](/static-files/b2819367-fa11-49d6-a363-d07bbe357f52) [View HTML](/node/11061/html)  \nNov 15, 2024 | [3](/sec-filings/sec-filing/3/0001104659-24-119737) | Initial filing by director officer or owner of more than ten percent |  [0001104659-24-119737.pdf](/static-files/93e26464-3c09-4298-b217-708c8c8ecfb2) [0001104659-24-119737.rtf](/static-files/20dedd81-1ca0-421d-b4c2-d368c6cc0058) [0001104659-24-119737.xls](/static-files/ed2fd2da-3ede-4886-b77b-3c0a12d16210) [View HTML](/node/11056/html)  \nNov 14, 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001839882-24-039023) | An amendment to the SC 13G filing |  [0001839882-24-039023.pdf](/static-files/c8df3e14-f9e6-40c6-a6c0-c767f8eb4aff) [0001839882-24-039023.rtf](/static-files/fcf44e77-037d-4470-9b59-8141b4c87e53) [0001839882-24-039023.xls](/static-files/2f30baf8-fe07-4b1f-83e1-e2374b91434a) [View HTML](/node/11046/html)  \nNov 14, 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000935836-24-000693) | An amendment to the SC 13G filing |  [0000935836-24-000693.pdf](/static-files/0710ab3d-3dde-4a66-b1a2-eb304edfa6bc) [0000935836-24-000693.rtf](/static-files/df32bcde-9221-4eda-a047-1107e88a0d1d) [0000935836-24-000693.xls](/static-files/b3c290f6-702b-4a41-af97-07e3b93bf701) [View HTML](/node/11051/html)  \nNov 07, 2024 | [8-K](/sec-filings/sec-filing/8-k/0000950170-24-123350) | Report of unscheduled material events or corporate event |  [0000950170-24-123350.pdf](/static-files/5161b32b-8a17-4455-9bc7-dd6212dad33f) [0000950170-24-123350.rtf](/static-files/f1282017-9745-42f4-8297-f706b5006fc1) [0000950170-24-123350.xls](/static-files/2e3aee9a-19f5-4fc6-8219-8a1a1f97411c) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0000950170-24-123350) [View HTML](/node/11036/html)  \nNov 07, 2024 | [10-Q](/sec-filings/sec-filing/10-q/0000950170-24-123338) | Quarterly report which provides a continuing view of a company's financial position |  [0000950170-24-123338.pdf](/static-files/f40258c6-68a2-4c56-a9aa-b35a92a5548c) [0000950170-24-123338.rtf](/static-files/7e8e0bc9-e9b0-4e7e-b9c8-e526508592ac) [0000950170-24-123338.xls](/static-files/9349620c-0df2-4aae-95c5-a491e368138c) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0000950170-24-123338) [View HTML](/node/11041/html)  \nNov 06, 2024 | [SC 13D/A](/sec-filings/sec-filing/sc-13da/0001104659-24-114818) | An amendment to a SC 13D filing |  [0001104659-24-114818.pdf](/static-files/c04fbf18-a3ee-441f-8b69-8c21ae906fdf) [0001104659-24-114818.rtf](/static-files/ca9d5f6c-cd7f-4d9a-9ea3-f257f97af867) [0001104659-24-114818.xls](/static-files/00c3ec8f-79b3-4540-8c79-96ac2d741d54) [View HTML](/node/11026/html)  \nOct 29, 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001493152-24-042959) | An amendment to the SC 13G filing |  [0001493152-24-042959.pdf](/static-files/ddca17a5-ad43-4a41-844f-4cacbba87d07) [0001493152-24-042959.rtf](/static-files/c1a9f682-504c-4d3c-9b0c-b46222341b76) [0001493152-24-042959.xls](/static-files/e909cdc0-ce8e-4e88-9549-867ca49cc4d3) [View HTML](/node/11016/html)  \nOct 28, 2024 | [8-K](/sec-filings/sec-filing/8-k/0000950170-24-117576) | Report of unscheduled material events or corporate event |  [0000950170-24-117576.pdf](/static-files/6a318b97-6d77-4af8-b35c-51d626331451) [0000950170-24-117576.rtf](/static-files/93e96333-9ae0-4a62-9829-539dcd292313) [0000950170-24-117576.xls](/static-files/7261a893-1020-4e44-ae84-e81a1a5d7ae9) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0000950170-24-117576) [View HTML](/node/11011/html)  \nOct 22, 2024 | [8-K](/sec-filings/sec-filing/8-k/0000950170-24-116111) | Report of unscheduled material events or corporate event |  [0000950170-24-116111.pdf](/static-files/a932c0be-0d3d-410a-b8bf-ac4815f4bdab) [0000950170-24-116111.rtf](/static-files/6c6791cd-bc50-4ba4-8f80-d2f04dd9987c) [0000950170-24-116111.xls](/static-files/2291e0f7-c26d-4d68-a5c5-b2a410a516ac) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0000950170-24-116111) [View HTML](/node/10986/html)  \n  \nDisplaying 1 - 10 of 573 results\n\n[Go to Top](#)\n\n[Go to Top](#)\n"
        }
      ]
    },
    {
      "section_name": "Stock Information",
      "links": [
        {
          "title": "Stock Information",
          "url": "https://evokepharmainc.gcs-web.com/stock-information",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Evoke Pharma](/sites/g/files/knoqqb59611/themes/site/nir_pid1515/client/images/EVOKE-PC.png) ![Evoke Pharma](/sites/g/files/knoqqb59611/themes/site/nir_pid1515/client/images/EVOKE-PC.png) ](https://devevokepharma.wpengine.com/)\n\n[](#)\n\n[evokepharma](https://www.evokepharma.com/author/evokepharma/ \"Posts by evokepharma\")\n\n#  Stock Information \n\n## Stock Quote ()\n\nPrevious Close  \n---  \nOpen  \nVolume  \nExchange  \n  \nDay High  \n---  \nDay Low  \n52-Week High  \n52-Week Low  \n  \n## Stock Chart\n\nMinimum 15 minutes delayed. Source: LSEG\n\n[Sign up for email alerts.](/email-alerts)\n\n[Go to Top](#)\n\n[Go to Top](#)\n"
        }
      ]
    },
    {
      "section_name": "Documents",
      "links": [
        {
          "title": "ACG 2024 Poster Presentation - GIMOTI & GLP-1 Users with DGP",
          "url": "https://evokepharmainc.gcs-web.com/static-files/8671cab0-a815-4bca-9da5-917fd9e0f202",
          "content": "\n"
        },
        {
          "title": "August 2024 Corporate Presentation",
          "url": "https://evokepharmainc.gcs-web.com/static-files/198bc774-ba37-47cb-8f3b-d3b8432c04cf",
          "content": "\n"
        },
        {
          "title": "Evoke 4Q /FY 2023 Earnings Presentation",
          "url": "https://evokepharmainc.gcs-web.com/static-files/a8c9677b-4232-4067-9259-debc8d396592",
          "content": "\n"
        }
      ]
    },
    {
      "section_name": "Events",
      "links": [
        {
          "title": "H.C. Wainwright 26th Annual Global Investment Conference Presentation",
          "url": "https://evokepharmainc.gcs-web.com/events/event-details/hc-wainwright-26th-annual-global-investment-conference-presentation",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Evoke Pharma](/sites/g/files/knoqqb59611/themes/site/nir_pid1515/client/images/EVOKE-PC.png) ![Evoke Pharma](/sites/g/files/knoqqb59611/themes/site/nir_pid1515/client/images/EVOKE-PC.png) ](https://devevokepharma.wpengine.com/)\n\n[](#)\n\n[evokepharma](https://www.evokepharma.com/author/evokepharma/ \"Posts by evokepharma\")\n\n#  Event Details \n\n# Events & Presentations\n\n## H.C. Wainwright 26th Annual Global Investment Conference Presentation\n\n###  Sep 9, 2024 at 7:00 AM EDT\n\n[Listen to webcast](https://journey.ct.events/view/f6e67369-32f5-40ec-91ee-c0a094660fb0)\n\n[Go to Top](#)\n\n[Go to Top](#)\n"
        },
        {
          "title": "Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications",
          "url": "https://evokepharmainc.gcs-web.com/events/event-details/evoke-pharma-host-virtual-key-opinion-leader-kol-webinar-evolving-landscape",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Evoke Pharma](/sites/g/files/knoqqb59611/themes/site/nir_pid1515/client/images/EVOKE-PC.png) ![Evoke Pharma](/sites/g/files/knoqqb59611/themes/site/nir_pid1515/client/images/EVOKE-PC.png) ](https://devevokepharma.wpengine.com/)\n\n[](#)\n\n[evokepharma](https://www.evokepharma.com/author/evokepharma/ \"Posts by evokepharma\")\n\n#  Event Details \n\n# Events & Presentations\n\n## Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications\n\n###  Apr 24, 2024 at 12:00 PM EDT\n\n[Watch the webcast](https://event.on24.com/wcc/r/4569146/B4EE603099F564F5E72F2B8224AF8FAB)\n\n[Go to Top](#)\n\n[Go to Top](#)\n"
        }
      ]
    }
  ]
}